The vaccine is a “double whammy” against viral infection, Pulendran said. The prolonged innate response lowers the amount of virus in the lungs by 700-fold. And viruses that slip through this initial defense are met with a swift adaptive response in the lungs.
On Tuesday, Nitra announced a $50 million Series B round, bringing its total capital raised to $205 million. The funding comes alongside a milestone: the company’s platform has surpassed $1 billion in annualized processing volume and crossed $33 million in annual recurring revenue as of December 2025, representing approximately eight-fold year-over-year growth. More than 700 clinics are now live on the platform.
，更多细节参见新收录的资料
В России допустили «второй Чернобыль» в Иране22:31
Что думаешь? Оцени!